Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06074094
Other study ID # probiotic and NAFLD
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 12, 2021
Est. completion date March 1, 2023

Study information

Verified date June 2023
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

this study aimed to evaluate the effectiveness of Probiotics supplementation (lactobacillus) on NAFLD fibrosis score.


Description:

Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by accumulation of fat (> 5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. NAFLD can cause liver inflammation and progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular carcinoma (HCC). The global prevalence of NAFLD in adults is estimated to be approximately 25%.The prevalence of NAFLD increases with increasing body mass index. in 2012 Chalasani et al, reported that 67% of overweight and 94% of obese individuals have NAFLD. There is a consensus regarding increasing worldwide prevalence of NAFLD and its impact on health, especially the progression to liver cirrhosis and hepatocellular carcinoma. Longitudinal studies of NAFLD have reported an increase in all-cause mortality, cardiovascular mortality, and liver-related mortality , NAFLD carries a large economic burden and therefore poor health-related quality of life. Lifestyle changes (diet and exercise) are the major and first suggestions of the guidelines ,as regard pharmaceutical interventions, agents with potential benefit in NASH include thiazolidinediones (TZDs), statins although they are well recognized in the treatment of dyslipidemia, their use as a specific treatment for NAFLD is not well evidenced. There is some data suggest that disruptions in the gut microbiome may play a role in the pathogenesis of NAFLD and progressions to NASH. A probiotic is a live microbial culture or cultured dairy product, which plays an important role in health. Probiotics for the treatment of NAFLD are seemingly a promising treatment option. Relatively easy availability, low cost, and absence of serious side effects make probiotics a lucrative choice. liver biopsy remains the gold standard for NAFLD diagnosis but it is impractical as a diagnostic tool because it is invasive and expensive. NAFLD fibrosis score constructed from routine clinical and laboratory variables can accurately predict the presence or absence of advanced fibrosis in NAFLD.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 1, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Age between18 and 60 - BMI = 25 kg/m2 - Sonographic findings of NAFLD +/- elevated liver enzymes (not more than 2 folds increase). Exclusion Criteria: - ? Any evidence of chronic liver diseases including viral hepatitis (B and C), auto immune hepatitis. - History of alcohol drinking. - Chronic medication use (drugs that cause elevated liver enzymes, recent antibiotic use or paracetamol use in the last month) - Persistent elevation of liver enzymes for 3 months. - History of DM. - History of statin therapy for cardiovascular disease (CVD). - History of recent operation. - History of gastroenteritis or diarrhea in the last 2 week.

Study Design


Related Conditions & MeSH terms

  • NAFLD
  • Non-alcoholic Fatty Liver Disease

Intervention

Drug:
Control Test
Lacteol fort 10 billion which contains culture medium and lactobacillus LS as active ingredients

Locations

Country Name City State
Egypt Ain Shams University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary non alcoholic fatty liver disease (NAFLD) fibrosis score NAFLD fibrosis score constructed from routine clinical and laboratory variables can accurately predict the presence or absence of advanced fibrosis in NAFLD This scoring system had an area under the ROC curve of 0.88 (95% CI 0.85-0.92). 2 cutoff points were selected to identify the presence (> 0.676) and absence (< -1.455) of significant fibrosis. 12 week of probiotic supplementation
Secondary ALT , AST effect of probiotic on ALT and AST 12 week of probiotic supplementation
Secondary body mass index (BMI) effect of probiotic on body mass index (BMI) 12 week of probiotic supplementation
See also
  Status Clinical Trial Phase
Completed NCT06101433 - The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A N/A
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Active, not recruiting NCT05479721 - LITMUS Imaging Study
Completed NCT05527938 - Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children N/A
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Completed NCT02654977 - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Phase 2
Completed NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Phase 2
Completed NCT06047847 - Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption N/A
Active, not recruiting NCT03534908 - Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
Recruiting NCT06098417 - Biomarkers in the Diagnosis and Prognosis of NAFLD
Recruiting NCT04564391 - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins N/A
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Not yet recruiting NCT05052515 - The Effects of Natural Extracts Supplementation on NASH Patients N/A
Recruiting NCT02459496 - Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus N/A
Completed NCT01936779 - Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans N/A
Completed NCT05844137 - Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes N/A
Recruiting NCT04664036 - Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
Recruiting NCT04976283 - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver Phase 4
Recruiting NCT03587298 - Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
Completed NCT02952170 - Impact of Weight Loss Surgery in Adolescents With NAFLD N/A

External Links